Homocysteine and Reclassification of Cardiovascular Disease Risk

被引:332
作者
Veeranna, Vikas [1 ,2 ]
Zalawadiya, Sandip K. [1 ,2 ]
Niraj, Ashutosh [1 ,2 ]
Pradhan, Jyotiranjan [1 ,2 ]
Ference, Brian [1 ,2 ]
Burack, Robert C. [2 ]
Jacob, Sony [1 ,2 ]
Afonso, Luis [1 ,2 ]
机构
[1] Wayne State Univ, Div Cardiol, Detroit Med Ctr, Detroit, MI 48201 USA
[2] Wayne State Univ, Dept Internal Med, Detroit Med Ctr, Detroit, MI 48201 USA
关键词
cardiovascular risk; homocysteine; risk reclassification; CORONARY-HEART-DISEASE; ARTERY CALCIUM SCORE; C-REACTIVE PROTEIN; FOLIC-ACID; SERUM HOMOCYSTEINE; PREDICTIVE-VALUE; ISCHEMIC-STROKE; PERFORMANCE; POPULATION; MORTALITY;
D O I
10.1016/j.jacc.2011.05.028
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objectives The purpose of this study was to examine whether adding homocysteine (Hcy) to a model based on traditional cardiovascular disease (CVD) risk factors improves risk classification. Background Data on using Hcy to reclassify individuals in various risk categories beyond traditional approaches have not been adequately scrutinized. Methods We performed a post hoc analysis of the MESA (Multi-Ethnic Study of Atherosclerosis) and NHANES III (National Health and Nutrition Examination Survey III) datasets. Hcy was used to predict composite CVD and hard coronary heart disease (CHD) events in the MESA study and CVD and CHD mortality in the NHANES III survey using adjusted Cox-proportional hazard analysis. Reclassification of CHD events was performed using a net reclassification improvement (NRI) index with a Framingham risk score (FRS) model with and without Hcy. Results Hcy level (>15 mu mol/l) significantly predicted CVD (adjusted hazard ratio [aHR]: 1.79, 95% confidence intervals [CI]: 1.19 to 1.95; p = 0.006) and CHD events (aHR: 2.22, 95% CI: 1.20 to 4.09; p = 0.01) in the MESA trial and CVD (aHR: 2.72, 95% CI: 2.01 to 3.68; p < 0.001) and CHD mortality (aHR: 2.61, 95% CI: 1.83 to 3.73; p < 0.001) in the NHANES III, after adjustments for traditional risk factors and C-reactive protein. The level of Hcy, when added to FRS, significantly reclassified 12.9% and 18.3% of the overall and 21.2% and 19.2% of the intermediate-risk population from the MESA and NHANES cohorts, respectively. The categoryless NRI also showed significant reclassification in both MESA (NRI: 0.35, 95% CI: 0.17 to 0.53; p < 0.001) and NHANES III (NRI: 0.57, 95% CI: 0.43 to 0.71; p < 0.001) datasets. Conclusions From these 2 disparate population cohorts, we found that addition of Hcy level to FRS significantly improved risk prediction, especially in individuals at intermediate risk for CHD events. (J Am Coll Cardiol 2011; 58: 1025-33) (C) 2011 by the American College of Cardiology Foundation
引用
收藏
页码:1025 / 1033
页数:9
相关论文
共 39 条
[1]
DETERMINATION OF FREE AND TOTAL HOMOCYSTEINE IN HUMAN-PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION [J].
ARAKI, A ;
SAKO, Y .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1987, 422 :43-52
[2]
Effects of Homocysteine-Lowering With Folic Acid Plus Vitamin B12 vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors A Randomized Trial [J].
Armitage, Jane M. ;
Bowman, Louise ;
Clarke, Robert J. ;
Wallendszus, Karl ;
Bulbulia, Richard ;
Rahimi, Kazem ;
Haynes, Richard ;
Parish, Sarah ;
Sleight, Peter ;
Peto, Richard ;
Collins, Rory .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (24) :2486-2494
[3]
Multi-ethnic study of atherosclerosis: Objectives and design [J].
Bild, DE ;
Bluemke, DA ;
Burke, GL ;
Detrano, R ;
Roux, AVD ;
Folsom, AR ;
Greenland, P ;
Jacobs, DR ;
Kronmal, R ;
Liu, K ;
Nelson, JC ;
O'Leary, D ;
Saad, MF ;
Shea, S ;
Szklo, M ;
Tracy, RP .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (09) :871-881
[4]
Homocysteine lowering and cardiovascular events after acute myocardial infarction [J].
Bonaa, KH ;
Njolstad, I ;
Ueland, PM ;
Schirmer, H ;
Tverdal, A ;
Steigen, T ;
Wang, H ;
Nordrehaug, JE ;
Arnesen, E ;
Rasmussen, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (15) :1578-1588
[5]
In search of fewer independent risk factors [J].
Brotman, DJ ;
Walker, E ;
Lauer, MS ;
O'Brien, RG .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (02) :138-145
[6]
*CDCP, DAT ACC NHANES 3 LIN
[7]
Centers for Disease Control and Prevention, About the National Health and Nutrition Examination Survey
[8]
Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis [J].
Clarke, R ;
Collins, R ;
Lewington, S ;
Donald, A ;
Alfthan, G ;
Tuomilehto, J ;
Arnesen, E ;
Bonaa, K ;
Blacher, J ;
Boers, GHJ ;
Bostom, A ;
Bots, ML ;
Grobee, DE ;
Brattström, L ;
Breteler, MMB ;
Hofman, A ;
Chambers, JC ;
Kooner, JS ;
Coull, BM ;
Evans, RW ;
Kuller, LH ;
Evers, S ;
Folsom, AR ;
Freyburger, G ;
Parrot, F ;
Genst, J ;
Dalery, K ;
Graham, IM ;
Daly, L ;
Hoogeveen, EK ;
Kostense, PJ ;
Stehouwer, CDA ;
Hopknis, PN ;
Jacques, P ;
Selhub, J ;
Luft, FC ;
Jungers, P ;
Lindgren, A ;
Lolin, YI ;
Loehrer, F ;
Fowler, B ;
Mansoor, MA ;
Malinow, MR ;
Ducimetiere, P ;
Nygard, O ;
Refsum, H ;
Vollset, SE ;
Ueland, PM ;
Omenn, GS ;
Beresford, SAA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16) :2015-2022
[9]
Multiple biomarker panels for cardiovascular risk assessment [J].
de Lemos, James A. ;
Lloyd-Jones, Donald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (20) :2172-2174
[10]
Use of Framinghamrisk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study [J].
de Ruijter, Wouter ;
Westendorp, Rudi G. J. ;
Assendelft, Willem J. J. ;
den Elzen, Wendy P. J. ;
de Craen, Anton J. M. ;
le Cessie, Saskia ;
Gussekloo, Jacobijn .
BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 :219-222